Frontiers of care

AIFA has given the go-ahead for acalabrutinib in combination with venetoclax. The drug has also been given the green light, in combination with chemo-immunotherapy, for the rarer mantle cell lymphoma

Chronic lymphocytic leukaemia: a new targeted ‘combination’ for first-line treatment

More than 750 free dermatological examinations and consultations at the Open Day organised in 90 hospitals by Fondazione Onda with Sidemast and under the patronage of Apiafco to raise awareness of the disease and quality of life for sufferers

Psoriasis high impact in 70% of cases but up to 60% of sufferers drop out of treatment

For the 'fourth leg' of cancer treatment, along with surgery, chemo- and radiotherapy, the prospects for use are widening: triple extension of reimbursability for the immunotherapy molecule pembrolizumab, which becomes usable in 28 different treatment scenarios

Cervical, endometrial and urothelial cancers, how immunotherapy changes treatment strategies

At the Ministry of Health, the inaugural event of the campaign for Rare Disease Day 2026: institutions and patient associations value treatments that improve the conditions of patients and families, but late diagnoses and territorial inequalities also in neonatal screening remain the key issues

In Italy there are over two million people with a rare disease, around 300 million worldwide

In Florence the Breastision event, a national summit on precision therapies in metastatic breast cancer

Metastic breast cancer: increasingly precise treatment thanks to liquid biopsy

News in the treatment of the form that does not affect muscle Immunotherapy may improve the results of BCG alone for disease-free survival

Bladder cancer, better control with immunotherapy drug combined with standard treatment

From target population estimation to economic impact assessments: the sharing of key information by the agency would reduce the use of personnel involved in regional policies by almost 40% on average

Faster and more efficient access to medicines with better dialogue between Aifa and the regions

Green light for first-line treatment of patients with metastatic non-small cell lung cancer and EGFR mutation